Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures

Patients with congenital Factor XIII (FXIII) deficiency have impaired fibrin stabilization and are at high risk for surgical bleeding. Data regarding the use of FXIII concentrates before and during surgery are lacking. The objective of this study was to report the use of plasma‐derived FXIII concentrate (Corifact in the United States; Fibrogammin P in other countries) in patients with congenital FXIII deficiency undergoing surgical procedures.

[1]  D. Nugent.  Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. , 2012, Thrombosis research.

[2]  É. Molnár,et al.  Measurement of factor XIII activity in plasma , 2012, Clinical chemistry and laboratory medicine.

[3]  M. Torchet,et al.  Successful long‐term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  S. Alexander,et al.  Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  D. Perry,et al.  A review of long‐term prophylaxis in the rare inherited coagulation factor deficiencies , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  M. Manco‐Johnson,et al.  Pediatric hemostasis and use of plasma components. , 2006, Best practice & research. Clinical haematology.

[7]  M. Blome,et al.  Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery , 2005, Thrombosis and Haemostasis.

[8]  T. Schnider,et al.  Decreased Factor XIII Availability for Thrombin and Early Loss of Clot Firmness in Patients with Unexplained Intraoperative Bleeding , 2004, Anesthesia and analgesia.

[9]  D. Perry,et al.  The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  P. Mannucci,et al.  Recessively inherited coagulation disorders. , 2004, Blood.

[11]  S. Kitchen,et al.  Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study , 2003, Journal of thrombosis and haemostasis : JTH.

[12]  P. Mannucci,et al.  Does negative heparin‐platelet factor 4 enzyme‐linked immunosorbent assay effectively exclude heparin‐induced thrombocytopenia? , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  V. Seifert,et al.  Increased Risk for Postoperative Hemorrhage After Intracranial Surgery in Patients With Decreased Factor XIII Activity: Implications of a Prospective Study , 2002, Stroke.

[14]  K. Lewis,et al.  Factor XIIIA and clot strength after cardiopulmonary bypass , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  P. Henriksson,et al.  FACTOR XIII DEFICIENCY , 1980, The Lancet.